IRD – opus genetics, inc. (US:NASDAQ)
Stock Stats
News
Opus Genetics (NASDAQ:IRD) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa
Opus Genetics (NASDAQ:IRD) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Opus Genetics (NASDAQ:IRD) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.
Opus Genetics Highlights 2025 Progress and Upcoming 2026 Catalysts
Form 4 Opus Genetics, Inc. For: Jan 22 Filed by: YERXA BENJAMIN R
Form 4 Opus Genetics, Inc. For: Jan 22 Filed by: SCHACHLE JOSEPH K
Form 4 Opus Genetics, Inc. For: Jan 22 Filed by: Zaremba Rabourn Amy
Form 4 Opus Genetics, Inc. For: Jan 22 Filed by: Magrath George
Form 4 Opus Genetics, Inc. For: Jan 22 Filed by: Jayagopal Ashwath
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.